Cardio and pulmonary fibrosis opens up a whole new ball
Cardio and pulmonary fibrosis opens up a whole new ball game. The mention of statistically significant reversal in fibrosis in three different studies is massive And shouldn’t be taken lightly. In fact, if I am a company looking at MASH or fibrosis in any organ system then I am picking up the phone and calling CYDY and saying hey, can we sit down and talk about what you’ve got?
It sounds like there are multiple parties sitting at the table and they haven’t decided on which one yet and because of that they put out a PR to make The shareholders happy. But this also puts the news out to the public and to other big Pharma companies Saying hey, we can reverse fibrosis and we believe we can across multiple organ systems and we are open to discussions about how to move forward with a partnership or partnerships.
No mention of Ozempic is interesting. In the first mouse study, they mentioned Resmiterom (MDGL) And the fact that LL was trending Towards a reversal in fibrosis And now we have statistically significant proof. And the prospectus from last fall said that there was a threefold decrease in fat deposits in the liver . This is also very significant news .
So I am assuming that because they did not mention that they were better than Ozempic there could be a synergistic effect With Ozempic and LL. And that makes me think Novo is still sitting at the table, but CYDY put the data out there to tempt others into a Partnership discussion. Hello Eli Lilly and anyone else looking at fibrosis in other organs!
Partnership/licensing agreements take more time than most people want, and that dreaded anticipation word has to be acknowledged.
This last paragraph reads quite nicely when you think about a partnership:
“The Company intends to explore a number of potential synergies and partnership opportunities in the coming months as it furthers its clinical development pipeline, including opportunities that might explore the potential widespread applications for leronlimab as a treatment path for fibrosis in other organs.”
So they are acknowledging that partnerships take time, and I believe that there are several seats at the table that are filled, and there are more companies wanting to sit down and talk. After this press release, there should be more interest and I’m OK waiting As they entertain discussions and sort through the offers.
Sounds like Jay knows this thing is going to explode and he just telegraphed that to us.
Patience then Patients.
31
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...
Continue Reading
A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...
Continue Reading
Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...
Continue Reading
A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...
Continue Reading
August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...
Continue Reading
When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...
Continue Reading
Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...
Continue Reading
Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...
Continue Reading
Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...
Continue Reading
Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...
Continue Reading
Top 5 Most Recently Viewed Articles
Mauna Kea Technologies and its Innovative AI Patent Mauna Kea Technologies, the proud inventor of Cellvizio®, a revolutionary platform that blends probe and needle-based confocal laser endomicroscopy (p/nCLE), has taken a significant step forward in the realm of artificial intelligence in medical diagnostic procedures. Recently, the company announced the granting of a...
Continue Reading
Hot Chili Limited's Significant Progress at La Verde Hot Chili Limited (OTCQX: HHLKF) has obtained key regulatory approval to enhance the drill coverage of its La Verde copper-gold discovery. This exciting development comes as the company aims to broaden exploration activities in an area strategically important to its operations. Understanding the La Verde Project The La...
Continue Reading
The Lithium Debate: Rising Tensions at COP30 At the recent climate discussions, the dialogue took an unexpected turn, raising eyebrows among investors in various clean-tech sectors. For the first time in thirty years of United Nations climate negotiations, serious concerns emerged regarding the social and environmental risks associated with lithium mining, which is...
Continue Reading
Introducing Edible Garden's Organic Product Line Edible Garden AG Incorporated has been making headlines as a leader in controlled environment agriculture (CEA). Recently, they launched their USDA Organic herb product line at Green’s Natural Foods and The Extra Supermarket, which is a significant step in their mission to provide sustainably grown and organic produce....
Continue Reading
Understanding the Rise of Riot Platforms Investors seeking substantial growth often look to companies like Riot Platforms (NASDAQ: RIOT), which has demonstrated impressive performance over the past five years. With a remarkable annualized return of 46.95%, Riot has outpaced the market by over 34.28%. This consistent growth contributes to a current market capitalization of...
Continue Reading